IFI-M · CSB Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-02194 // MULTI-AXIS · IFI-M

CSB Tri-Axis Dominant-Primary Series IV-IV

Mentha × piperita

Peppermint

Tier IVCSB Tri-Axis Dominant-Primary Series

Target Trait

2.38×

fold-change

Cooling-dominant tri-axis S+B modulated fold-change

Technical Specifications

SKU

SS-F-M3-02194

Genomic Edits

11

GC Content

43.6%

Construct Length

6,114 bp

Promoter System

T7/SP6 cell-free

Expression System

In-vitro cell-free

Host Strain

Cell-free

Receptor Target

TRPM8 + TAS1R2/TAS1R3 + TAS2R38 (suppression)

IFI Score

238

Pathway Edits

  • TRPM8 pathway primary gene cluster for cooling (IFI-C) tri-axis component
  • TAS1R2/TAS1R3 pathway primary gene cluster for sweet (IFI-S) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent CSB pathway operation
  • Cross-pathway regulatory circuit for cooling-dominant CSB triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPM8, TAS1R2/TAS1R3, and TAS2R38 (suppression) pathways simultaneously engineeredCooling-dominant tri-axis expression strategy (CSB) with cross-pathway flux managementCell-free co-translation of multi-axis enzyme sets for in-vitro biochemical validation

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier IV CSB triple-axis construct for advanced multi-modal sensory architecture combining cooling, sweet, and bitter-attenuation axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$3999 · Tier IV License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?